Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SHSY5Y neuroblastoma cells: Role of nicotinic receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 3, 2005, Pages 1346-1353

  Arias, Esperanza ^a   Gallego Sandín, Sonia ^a,b   Villarroya, Mercedes ^a   García, Antonio G ^a,b   López, Manuela G ^a,b,c  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; BETA SECRETASE; CHOLINESTERASE INHIBITOR; DIHYDRO BETA ERYTHROIDINE; DONEPEZIL; GALANTAMINE; METHYLLYCACONITINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; OKADAIC ACID; RIVASTIGMINE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; PRIORITY JOURNAL; TOXICITY;

EID: 27744436607     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.090365     Document Type: Article

References (38)

1. Aguglia E, Onor ML, Saina M, and Maso E (2004) An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 20:1747-1752.
2. Akasofu S, Kosasa T, Kimura M, and Kubota A (2003) Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol 472:57-63.
3. Arias E, Ales E, Gabilan NH, Cano-Abad MF, Villarroya M, Garcia AG, and Lopez MG (2004) Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46:103-114.
4. Arriagada PV, Growdon HH, Hedley-White ET, and Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:633-639.
5. Belluardo N, Mudo G, Blum M, and Fuxe K (2000) Central nicotinic receptors, neurotrophic factor and neuroprotection. Behav Brain Res 113:21-34.
6. Belluardo N, Olsson PA, Mudo G, Sommer WH, Amato G, and Fuxe K (2005) Transcription factor gene expression profiling after acute intermittent nicotine treatment in the rat cerebral cortex. Neuroscience 133:787-796.
7. Billings LM, Oddo S, Green KN, McGaugh JL, and Laferla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45:675-688.
8. Capsoni S, Giannotta S, and Cattaneo A (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA 99:12432-12437.
9. 2+ stores. J Neurochem 81:606-614.
10. Di Angelantonio S, Bernardi G, and Mercuri NB (2004) Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones. Br J Pharmacol 141:644-652.
11. Dispersyn G, Nuydens R, Connors R, Borgers M, and Geerts H (1999) Bcl-2 protects against FCCP-induced apoptosis and mitochondrial membrane potential depolarization in PC12 cells. Biochim Biophys Acta 1428:357-371.
12. Donnelly-Roberts DL and Brioni JD (1998) Preclinical evidence on the neuroprotective effects of nicotinic ligands, in Neuronal Nicotinic Receptors Pharmacology and Therapeutic Opportunities (Arneric SP and Brioni JD eds) pp 337-348, Wiley-Liss, Inc., New York.
13. Dorronsoro I, Alonso D, Castro A, del Monte M, Garcia-Palomero E, and Martinez A (2005) Synthesis and biological evaluation of tacrine- thiadiazolidinone hybrids as dual acetylcholinesterase inhibitors. Arch Pharm (Weinheim) 338:18-23.
14. Giacobini E (2003) Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 28:515-522.
15. Greig NH, Sambamurti K, Yu Q, Perry TA, Holloway HW, Haberman F, Brossi A, Ingram DK, and Lahiri DK (2003) Butyrylcholinesterase: its selective inhibition and relevance to Alzheimer's disease therapy, in Butyrylcholinesterase: Its Function and Inhibitors (Giacobini E ed) pp 69-90, Martin Dunitz, London.
16. Hernandez CM and Terry AV Jr (2005) Repeated nicotine exposure in rats: effects on memory function, cholinergic markers and nerve growth factor. Neuroscience 130:997-1012.
17. Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, and Shimohama S (2004) Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. Biochem Biophys Res Commun 325:976-982.
18. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, and Akaike A (2001) α7 Nicotinic receptor transduces signals PI3 kinase to block Ab-induced neurotoxicity. J Biol Chem 276:13541-13546.
19. Lahiri DK and Farlow MR (1996) Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci 7:41-49.
20. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, and McKeith IG (1994) Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 5:747-749.
21. 2+ influx in Bcl-2 overexpressing cells. J Cell Biol 148:857-862.
22. 2+ concentration of the endoplasmic reticulum is a key determinant of ceramideinduced apoptosis: significance of the molecular mechanism of Bcl-2 action. EMBO (Eur Mol Biol Organ) J 20:2690-2701.
23. Price JL, Davis PB, Morris JC, and White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 12:295-312.
24. Recuero M, Serrano E, Bullido MJ, and Valdivieso F (2004) Abeta production as consequence of cellular death of a human neuroblastoma overexpressing APP. FEBS Lett 570:114-118.
25. Robinson JP, Darzynkiewicz Z, Dean PN, Orfao A, Rabinovitch PS, Stewart CC, Tanke HJ, and Weeless LL (1997) Current Protocols in Cytometry, John Wiley & Sons, Inc., New York.
26. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, and Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6.
27. Sobrado M, Roda JM, Lopez MG, Egea J, and Garcia AG (2004) Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett 365:132-136.
28. Soreq H and Seidman S (2001) Acetylcholinesterase-new roles for an old actor. Nat Rev Neurosci 2:294-302 [Erratum: Nat Rev Neurosci 2:670].
29. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, and Akaike A (2003) Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306:772-777.
30. Terry RD (1998) The cytoskeleton in Alzheimer disease. J Neural Transm Suppl 53:141-145.
31. Terry RD, Masliah E, Salmon DP, Butters N, De Teresa R, Hill R, Hansen LA, and Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580.
32. Terry RD, Peck A, De Teresa R, Schechter R, and Horowpian DS (1981) Some morphometric aspects of the brain on senile dementia of the Alzheimer type. Ann Neurol 10:184-192.
33. Tian Q, Lin ZQ, Wang XC, Chen J, Wang Q, Gong CX, and Wang JZ (2004) Injection of okadaic acid into the Meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience 126:277-284.
34. Tiraboschi P, Hansen LA, Thal LJ, and Corey-Bloom J (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62:1984-1989.
35. Uberti D, Rizzini C, Spano PF, and Memo M (1997) Characterization of tau proteins in human neuroblastoma SH-SY5Y cell line. Neurosci Lett 235:149-153.
36. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, and Huang Z (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97:7124-7129.
37. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, and Kershaw P (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20:777-789.
38. Wilcock GK, Lilienfeld S, and Gaens E (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicenter randomised controlled trial. Galantamine International-1 Study Group. BMJ 321:1445-1449.